One Step Ahead

The Respiratory DMI Kit supports quick antibiotic therapy decisions as it provides identification results directly from native respiratory patient samples such as sputum, endotracheal or bronchial aspirates without prior bacterial culture.

The assay design of 12 genus and species-specific probes enables easy, precise and reproducible identification of clinically relevant pathogens associated with the development of HAP and ventilator-associated pneumonia (VAP) within 35 minutes. Slides can be read manually or automatically scanned and imaged with the Metafer DMI Scanner.

With Further Insights

Gram stains, together with rapid DMI results, provide timely, strong, reliable and cost-effective support for antibiotic selection with valuable information about the principle bacteria associated with nosocomial pneumonia (HAP / VAP). Moreover, DMI has the important advantage over other molecular diagnostics of preserving cell morphology, allowing phenotypic examination.

At Reduced Costs

Early HAP / VAP pathogen identification provides significant cost-savings potential because it supports the timely selection of appropriate antibiotics based on commonly known resistance characteristics. And the swift selection of further specific tests for identified pathogens, such as resistance assays for S. aureus, can reduce unnecessary concomitant treatment costs and saves time and resources.

Back to microbiology applications page